YFY Biotech Management Company
YFY Biotech Management Company, established in 2003, serves as the corporate venture capital arm of Yuen Foong Yu Paper Manufacturing Company in Taipei, Taiwan. The company concentrates on the bio-pharmaceutical, diagnostics, medical device, and healthcare technology sectors. YFY Biotech specializes in various investment stages, including incubation, seed and startup funding, as well as early and later-stage investments, alongside growth and buyout opportunities. Its strategic focus enables it to support innovative companies and technologies within the life sciences field, contributing to advancements in healthcare solutions.
Omni-ID is a leading supplier of passive low-profile UHF RFID tags. The company is focused on delivering affordable high-performance tags that work reliably in harsh environments-including metals and liquids. Omni-ID technology affords customers complete accuracy in the identification and management of high value assets.
TaiGen Biotechnology Co., Ltd. is a pharmaceutical company based in Taipei, Taiwan, with operations extending to China and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of novel therapeutics aimed at treating infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug targeting community-acquired pneumonia and various skin infections; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, a treatment for influenza A and B. Additionally, TaiGen develops stem cell mobilizers for leukemia treatment and offers a range of antiviral and antibacterial agents. The company operates as a subsidiary of Taigen Biopharmaceuticals Holdings Limited.
TaiGen Biotechnology Co., Ltd. is a pharmaceutical company based in Taipei, Taiwan, with operations extending to China and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of novel therapeutics aimed at treating infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug targeting community-acquired pneumonia and various skin infections; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, a treatment for influenza A and B. Additionally, TaiGen develops stem cell mobilizers for leukemia treatment and offers a range of antiviral and antibacterial agents. The company operates as a subsidiary of Taigen Biopharmaceuticals Holdings Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.